Caicun Zhou

机构：Tongji University, First Affiliated Hospital of Guangzhou Medical University, Tongren Hospital, Shanghai Pulmonary Hospital, Shanghai East Hospital, Wuhan Third Hospital, Jiangsu Province Hospital, Nanjing Medical University, Guangzhou Medical University · ORCID：0000-0002-1072-9941

发表论文 220 篇 · 总被引 8160 次 · h-index 43

代表论文

• Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST (2025 · Journal of Clinical Oncology · 被引 52)
• Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial (2025 · Journal of Clinical Oncology · 被引 44)
• Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches (2025 · Nature Reviews Clinical Oncology · 被引 33)
• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 26)
• CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer (2024 · Signal Transduction and Targeted Therapy · 被引 17)
• FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004) (2024 · Lung Cancer · 被引 7)